Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001689375-26-000021
Filing Date
2026-04-24
Accepted
2026-04-24 08:30:13
Documents
15
Period of Report
2026-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A trda-20260424.htm   iXBRL DEF 14A 653463
3 GRAPHIC trda-20260424_g1.jpg GRAPHIC 11306
4 GRAPHIC trda-20260424_g2.jpg GRAPHIC 9713
5 GRAPHIC trda-20260424_g3.jpg GRAPHIC 94943
6 GRAPHIC trda-20260424_g4.jpg GRAPHIC 80337
  Complete submission text file 0001689375-26-000021.txt   1479240

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trda-20260424.xsd EX-101.SCH 918
18 EXTRACTED XBRL INSTANCE DOCUMENT trda-20260424_htm.xml XML 3989
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40969 | Film No.: 26890585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)